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it is unknown whether early diagnosis of autosomal dominant polycystic kidney disease (ADpKD) can 
enable earlier management and improve outcomes. We conducted a post hoc analysis of data from the 
TEMPO 3:4 trial. Subjects were stratified by ADPKD diagnosis at age ≤18 (childhood diagnosis [CD]) 
or>18 (adulthood diagnosis [AD]). Groups were compared for baseline characteristics and total kidney 
volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline over 3 years. 294 CD and 
1148 AD subjects were analyzed. At inclusion, CD subjects were younger (mean age 34.2 versus 39.8 
years; p < 0.0001) and had better eGFR (mean ± SD 87.4 ± 23.9 versus 80.1 ± 20.7 mL/min/1.73 m2; 
p < 0.0001), while CD had more severe Mayo risk classification (p < 0.0001) and more PKD1 mutations 
(p = 0.003). No statistical differences were found in TKV or eGFR change. At study end, placebo-
treated CD subjects had better eGFR than projected by a prediction equation (mean difference ±SD 
for observed versus predicted eGFR: 2.18 ± 10.7 mL/min/1.73 m2; p = 0.0475). However, these results 
are not confirmed when excluding stage 1 CKD. Whether CD subjects, despite their risk profile, have a 
slower disease course than predicted remains inconclusive. Future studies are needed to confirm that 
early diagnosis and management can alter the disease course of ADPKD.
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by progressively 
enlarging cystic kidneys. The disease process starts prenatally but often remains pauci-symptomatic and with little 
or no detectable effect on kidney function during the first decades of life. As cyst burden increases, patients expe-
rience a gradual loss of functioning nephrons and are likely to experience burdensome symptoms such as kidney 
pain or abdominal distension. Eventually, the parenchymal destruction caused by cyst formation and growth 
leads to end stage renal disease (ESRD) in more than half of patients by the age of 601. Since cysts formed early in 
life contribute disproportionally to the final total cyst volume2, it might be argued that the best chance for preserv-
ing long-term renal function would be to start treatment at the first opportunity. At the same time, early diagnosis 
and follow-up in asymptomatic at-risk children remains controversial. Potential benefits of treatment need to be 
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balanced against factors such as psychological stress, legal/financial implications resulting from the knowledge of 
having a progressive disease, and potential adverse events of pharmacotherapy in a slowly progressing disease3.
Medications for ADPKD used to be limited to antihypertensive treatment with the goal of improving renal 
and cardiovascular outcomes4. The renin-angiotensin-aldosterone system (RAAS) is upregulated in APDKD 
and might contribute to cyst growth and kidney function decline. The use of RAAS-inhibitory antihypertensive 
agents in an early-stage population was shown to achieve a low blood pressure target and modestly inhibit the 
growth of total kidney volume (TKV)5. Recently, prospective studies in adult patients at risk for rapid ADPKD 
progression have demonstrated that vasopressin V2 receptor antagonism, which directly targets pathways 
implicated in ADPKD cystogenesis, significantly slows TKV increase and estimated glomerular filtration rate 
(eGFR) decline6–9. This has led to an entirely new treatment paradigm for adults with ADPKD. However, no 
disease-modifying therapeutic options are currently available for ADPKD patients younger than 18 years, and 
the potential benefits of early interventions like antihypertensive treatment and RAAS inhibition remain debated. 
Still, studies of disease-modifying treatments, such as an ongoing phase IIIb trial focusing on the safety and 
efficacy of tolvaptan in ADPKD-affected children aged 4 to 14 years (NCT02442674), may change the treatment 
paradigm for pediatric ADPKD patients.
At this point, data on the natural history of and prognostic indicators for childhood ADPKD are both largely 
lacking and urgently needed10–12. The Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes 
(TEMPO) 3:4 trial is one of the largest studies conducted in the field (N = 1445)6. The data from TEMPO 3:4 
include detailed medical histories and 3 years of prospective follow up. Given that 20% of the subjects in this 
cohort were diagnosed with ADPKD during childhood, the TEMPO 3:4 data represent a unique opportunity 
to evaluate the effect of early diagnosis on long-term renal outcomes. We evaluated the hypothesis that earlier 
diagnosis, and therefore potentially earlier initiation of renoprotective therapy, might have benefits over later 
diagnosis in terms of TKV and eGFR.
Materials and Methods
All methods were carried out in accordance with relevant guidelines and regulations. The institutional review 
board or ethics committee at each site approved the protocol; written informed consent was obtained from all 
participants. A full list of the TEMPO 3:4 investigators and trial sites is given in a Supplementary Appendix. 
The design of the TEMPO 3:4 study has been described previously6,13. In brief, this multicenter, randomized, 
double-blind, placebo-controlled, parallel-group trial enrolled a population of ADPKD-affected subjects (ages 
18–50 years) with relatively preserved eGFR but a high likelihood of rapid disease progression. Key inclusion 
criteria were creatinine clearance ≥60 mL/min, estimated by the Cockcroft-Gault formula, and TKV ≥ 750 mL. 
Participants were randomized in a 2:1 ratio to 3 years of treatment with tolvaptan or matching placebo, titrated to 
twice daily doses of 45/15 mg, 60/30 mg, or 90/30 mg, at the highest level tolerable to the subject.
Data collected during the trial included ADPKD medical history based on subject recollection and, where 
available, medical records (including the age of diagnosis and the initial symptom); vital signs; laboratory 
parameters (e.g., hematology, serum chemistry, urinalysis); and ADPKD-related outcomes such as kidney pain, 
worsening hypertension, and worsening albuminuria. Standardized MRI scans of the kidneys were obtained at 
baseline and at months 12, 24, and 36. Equations from the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) that are adjusted for ethnic group were used to estimate GFR14,15.
Subjects were stratified by age at ADPKD diagnosis ≤18 years (childhood diagnosis [CD]) and >18 years 
(adulthood diagnosis [AD]) and compared for baseline characteristics at study entry and for rates of TKV growth 
and eGFR decline during the 3-year study follow-up period. CD diagnosed subjects were considered symptomatic 
patients if the reason for diagnosis was high blood pressure, hematuria, urinary tract infection or kidney pain. 
The remaining subjects were considered asymptomatic at diagnosis. Statistical comparisons of changes in TKV 
and eGFR were derived using linear mixed models, in which the intercept had the fixed effect and the slope had 
both fixed and random effects (for change in TKV) or in which both intercept and slope had fixed and random 
effects (for change in eGFR).
Observed eGFR was compared to predicted eGFR for each subject based on the prediction model developed 
by Irazabal and colleagues16. Observed eGFR was the eGFR (CKD-EPI) value at last visit on treatment, and 
predicted eGFR was the value calculated based on the eGFR (CKD-EPI) value at end of titration/week 3, years 
from end of titration/week 3 to last visit on treatment, sex, age, and Mayo classification. The prediction equation 
is 21.18-0.23*year + [−1.26(if female)−0.26*age+0.90*eGFR+0.58(if class B)−1.14(if class C)−1.93(if class 
D)−6.26(if class E)] + [0.19(if female)−0.02*age+0.001*eGFR-1.33(if class B)−2.63(if class C)−3.48(if class 
D)−4.78(if class E)]*year16. A paired T-test was used to compare differences between observed and predicted 
eGFR.
We performed two sensitivity analyses, the first a linear mixed model with change in eGFR as outcome, 
adjusted for baseline differences (including AD versus CD) and their interactions with time. Second, we applied 
a recently developed mixed polynomial model to predict eGFR change over time17. The prediction model devel-
oped by Irazabal et al. assumes a linear relation between age and eGFR slope, whereas kidney function in ADPKD 
is relatively stable at young age and declines more rapidly later. The mixed polynomial model accounts for this 
nonlinearity.
Results
Baseline characteristics. The study population of TEMPO 3:4 included 294 (20%) CD subjects and 1148 
(80%) AD subjects at enrollment. The distribution of ages at diagnosis in the CD and AD groups is shown in 
Supplementary Fig. 1. Subject baseline characteristics are shown in Table 1.
CD subjects were significantly younger at time of study enrollment than AD subjects and had significantly bet-
ter eGFR. The distribution of CKD stages was, accordingly, milder in the CD subjects; the AD group had higher 
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proportions of subjects in CKD stages 2 and 3. Although the CD subjects were younger, they exhibited similar 
TKV to AD subjects, most likely due to the study inclusion criteria. Younger mean age and comparable TKV at 
study inclusion in the CD group relative to the AD group corresponded to a significantly worse Mayo risk class 
distribution in the CD group, with approximately 70% of the CD subjects and fewer than 50% of the AD subjects 
in classes 1D-1E. Data on genetic diagnosis in the two groups are shown in Table 2. At inclusion, proteinuria was 
present in 24.0% of the AD group and 24.8% in the CD group. The causes of diagnosis in the CD group are shown 
in Table 3. The cause of diagnosis in most subjects (70%) was categorized as “Others,” given that this information 
was not required to be collected.
Parameter
CD AD











(n = 386) Total (n = 1148)
Male sex, n (%) 99 (51) 48 (49) 147 (50) 395 (52) 203 (53) 598 (52) NS
RAASi use, n (%) 134 (68) 65 (66) 199 (68) 554 (73) 285 (74) 839 (73) NS
Hypertension, 
n (%) 158 (81) 80 (82) 238 (81) 627 (82) 325 (84) 952 (83) NS
CKD stage, n (%)* 0.0015†
CKD I 81 (41) 47 (48) 128 (44) 248 (33) 126 (33) 374 (33)
CKD II 83 (42) 42 (43) 125 (43) 381 (50) 182 (47) 563 (49)
CKD III 32 (16) 8 (8) 40 (14) 131 (17) 77 (20) 208 (18)
Mayo risk class, 
n (%)* <0.0001
†
1B 5 (2.6) 4 (4.1) 9 (3.1) 68 (8.9) 27 (7.0) 95 (8.3)
1 C 44 (22.4) 27 (27.6) 71 (24.1) 295 (38.7) 164 (42.5) 459 (40.0)
1D 75 (38.3) 31 (31.6) 106 (36.1) 257 (33.7) 130 (33.7) 387 (33.7)
1E 68 (34.7) 32 (32.6) 100 (34.0) 111 (14.6) 50 (13.0) 161 (14.0)
2 2 (1.0) 3 (3.1) 5 (1.7) 26 (3.4) 14 (3.6) 40 (3.5)
Mean age at 
inclusion (SD) 34.3 (8.0) 34.0 (8.3) 34.2 (8.1) 39.6 (6.4) 40.1 (6.2) 39.8 (6.4) <0.0001












1965) 1453 (1068,1990) 0.2545
Table 1. Clinical characteristics of childhood diagnosis and adulthood diagnosis subjects at enrollment in 
TEMPO 3:4. Age in years; eGFR in mL/min/1.73 m2, TKV in mL. *Includes subjects for whom the data were 
available. Percentages may not add up to 100. †p-value is for the distribution of CKD stages/Mayo risk classes 
for CD versus AD. AD, adulthood diagnosis; CD, childhood diagnosis; CKD, chronic kidney disease; IQR, 
interquartile range; NS, not significant.
CD (N = 294) 
n (%)




Genetic analysis 160 (54.4) 607 (53.1) NS
No mutation found 6 (3.8) 13 (2.1) NS
PKD1 147 (91.9) 508 (83.7) 0.003
Truncating 106 (66.2) 360 (59.3) NS
Non-Truncating 44 (27.5) 155 (25.5) NS
PKD2 7 (4.4) 86 (14.2) <0.001
Table 2. Genetic analysis. AD, adulthood diagnosis; CD, childhood diagnosis; NS, not significant.
Cause N = 294
Hypertension, n (%) 30 (10.2)
Hematuria, n (%) 14 (4.8)
Urinary tract infection, n (%) 21 (7.1)
Kidney pain, n (%) 26 (8.8)
Unknown, n (%) 12 (4.1)
Others, n (%) 207 (70.4)
Table 3. Reasons for diagnosis in the childhood diagnosis cohort. Rates of change in TKV and eGFR during the 
study.
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Consistent with the findings for the overall study population in TEMPO 3:4, tolvaptan was associated with 
significant decreases in the rates of TKV growth and eGFR decline in both the CD and AD subgroups (Fig. 1A). 
In a subsequent analysis, CD and AD subgroups within each study treatment arm were compared (Fig. 1B). To 
better discern intergroup differences, only subjects in CKD stages 2 or 3 were included in this eGFR comparison, 
as eGFR is more likely to decline at later CKD stages. There were no significant differences in rates of TKV growth 
or eGFR decline. In the placebo-treated arm, TKV growth and eGFR decline were milder in the CD subgroup 
versus the AD subgroup, but the differences were not significant. There were also no significant differences in 
eGFR decline between the CD and AD subgroups within each treatment arm when all subjects (CKD stages 1–3) 
were included in the comparison (data not shown).
To minimize potential bias from the use of arbitrary age categories (≤18 years and >18 years), a linear mixed 
models was performed using age at diagnosis as a continuous variable. Results did not show significant effects of 
age at diagnosis on the model (Supplementary Tables 1–3). A sensitivity analysis evaluating baseline characteris-
tics and their interactions with time, however, supported the association of age at diagnosis with eGFR outcome, 
yielding a significant age at diagnosis x time interaction (p = 0.0015) (Supplementary Table 4).
An additional analysis assessed for a possible impact of cause of ADPKD diagnosis among the CD subjects, 
given that outcomes might differ based on whether a patient is diagnosed early while asymptomatic (for exam-
ple, screening because of familial history) or because of symptoms associated with a more severe phenotype 
(hypertension, hematuria, urinary tract infection, or kidney pain). The subanalysis was conducted within the 
limitation that the reasons for diagnosis were unavailable for most subjects. As would be expected, hypertension 
and use of RAAS inhibitors were more common at study baseline in subjects diagnosed due to symptoms than in 
Figure 1. Annual TKV growth and change in eGFR: (A) for tolvaptan versus placebo within the childhood 
diagnosis and adulthood diagnosis subgroups; (B) for childhood diagnosis versus adulthood diagnosis subjects 
within the tolvaptan and placebo study arms (intention-to-treat subjects). *Excludes observations deemed 
unreliable by investigators: 19 outliers of 4759 data points in the placebo group and 16 outliers of 8564 data 
points in the tolvaptan group. †Subjects in CKD stages 2 or 3 (CKD stage 1 excluded). Excludes observations 
deemed unreliable by investigators. Error bars are standard deviation. AD, adulthood diagnosis; CD, childhood 
diagnosis; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular 
filtration rate; TKV, total kidney volume.
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asymptomatic subjects (Supplementary Table 5). Tolvaptan exerted significant effects on TKV increase and eGFR 
decline versus placebo in asymptomatic CD subjects but not in subjects diagnosed due to symptoms, possibly 
because of the small size of the analysis population (Supplementary Tables 6 and 7).
Next, the difference between observed and predicted eGFR values was plotted for CD and AD subjects (CKD 
stages 1–3) in each of the tolvaptan and placebo arms over the study follow-up period (Fig. 2). As might be 
expected, the observed eGFR was significantly higher than the predicted eGFR in tolvaptan-treated subjects 
(mean difference ± SD of 6.86 ± 11.1 mL/min/1.73 m2 [p < 0.0001] for CD and 4.40 ± 10.5 mL/min/1.73 m2 
[p < 0.0001] for AD). Interestingly, in placebo-treated subjects, the predicted eGFR was not different from the 
observed eGFR in AD subjects (mean difference ± SD of 0.07 ± 10.5 mL/min/1.73 m2 [p = 0.8995]). However, 
in the CD subjects, the observed eGFR at the end of follow up was significantly higher than the predicted eGFR 
(mean difference ± SD of 2.18 ± 10.7 mL/min/1.73 m2 [p = 0.0475]).
To account for differences between the AD and CD populations, additional analyses controlling for subject 
age at study inclusion, Mayo risk class, and CKD stage were conducted. Among a subgroup of AD and CD sub-
jects matched by Mayo risk class and age at study inclusion, the difference between observed and predicted eGFR 
was still significant in tolvaptan-treated subjects, whereas there was no significant difference in either AD or CD 
placebo-treated subjects (Supplementary Table 8). A subgroup analysis that excluded subjects at CKD stage 1 at 
baseline (i.e., included only subjects at CKD stages 2–4) yielded significant differences between observed and 
predicted eGFR in tolvaptan-treated AD and CD subjects, placebo-treated AD subjects, but not placebo-treated 
CD subjects (Supplementary Table 9). An analysis of CD subjects by reason for diagnosis (subjects diagnosed 
due to symptoms and other subjects) showed a significant difference between observed and predicted eGFR 
for tolvaptan-treated subjects but not placebo-treated subjects, possibly due to the small analysis population 
(Supplementary Table 10). Finally, a sensitivity analysis based on the mixed polynomial prediction model devel-
oped by Yu et al.17 found no significant differences in observed versus predicted eGFR in either tolvaptan- or 
placebo-treated subjects defined by age at diagnosis (Supplementary Table 11).
Discussion
We report the first post hoc analysis of long-term renal outcome data from a large ADPKD cohort diagnosed 
during childhood. The placebo group in particular represents a unique opportunity to study the natural history 
of ADPKD diagnosed in children. Twenty percent of the subjects studied in the TEMPO 3:4 trial were diagnosed 
with ADPKD at or before the age of 18 years. At the time of inclusion, the CD group was significantly younger, 
with a better eGFR but a similar TKV relative to the AD group. Consequently, the CD group had a significantly 
worse Mayo risk class distribution at enrollment. Significantly more PKD1 mutations were found in the CD 
group; inversely, more PKD2 mutations were found in the AD group. The younger age at inclusion of the CD 
group (34 years compared to 40 years, p < 0.0001) would be expected, given that the groups were defined based 
on their age at diagnosis.
Several arguments could be made that the CD group would be at risk for a more rapidly progressive form of 
ADPKD. While the higher eGFR in the CD subjects versus AD subjects could be explained by the younger aver-
age age of the CD group, the presence of compensatory hyperfiltration, a factor associated with renal progression, 
could be postulated18. It is assumed that in ADPKD, kidney function remains normal for several decades because 
of hyperfiltration by remaining healthy nephrons. Yet, hyperfiltration remains a poorly defined entity19, and a 
recent study in young, early-stage ADPKD patients did not demonstrate hyperfiltration, defined as a decreased 
difference in kidney function reserve capacity after a dopamine infusion20. The present study does not address the 
potential occurrence of compensatory glomerular hypertrophy.
CD subjects had significantly more severe Mayo class, as approximately 70% of the CD subjects and fewer than 
50% of the AD subjects were classes 1D-1E. A worse Mayo classification implies that a more progressive disease is 
expected. An increase in TKV is widely accepted as being the dominant feature of ADPKD progression, as TKV 
Figure 2. Observed–predicted eGFR (mL/min/1.73 m2) within the treatment period in the adulthood 
diagnosis and childhood diagnosis subgroups. AD, adulthood diagnosis; CD, childhood diagnosis; eGFR, 
estimated glomerular filtration rate.
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is inherently linked to the pathogenesis of PKD and represents a primary event rather than a secondary conse-
quence of disease-causing mutations21. Indeed, it was recently demonstrated that the proportion of the total effect 
of gene type that is mediated by Mayo class is 0.73, supporting the notion that PKD mutations cause loss of GFR 
predominantly by affecting kidney size17. A htTKV ≥600 mL/m at baseline predicts the development of stage 3 
CKD within 8 years22, and patients with higher rates of TKV growth at baseline have an increased frequency of 
ESRD after 10 years16. The predicting renal outcomes in ADPKD (PROPKD) model is unsuitable for assessing 
the risk of progression in the CD group, which had a mean age of 34 years, given that PROPKD scoring cannot be 
applied in patients aged <35 unless they have already experienced ADPKD-related clinical events23. More data 
on the progression of ADPKD and potential predictive risk markers early in life are needed.
Consistent with the more severe Mayo imaging classification, more subjects in the CD group had a PKD1 
mutation. It is well known that patients with PKD1 mutations in general have a more severe renal phenotype 
than patients with PKD2 mutations, reaching ESRD almost 20 years earlier24. It is thus possible that patients with 
PKD1 mutations are diagnosed earlier, e.g., in case of severe family history. Indeed, the TEMPO 3:4 trial included 
patients with a high likelihood of rapid progression and a selection bias for PKD1 mutations is suspected. Further, 
an early and rapidly progressive ADPKD phenotype might be in part explained by additional (hypomorph) muta-
tions in other ciliopathy genes25. Although these data are currently not available for the TEMPO 3:4 cohort, 
whole-genome sequencing might yield additional prognostic information in the CD population26.
No difference in hypertension and RAAS inhibition was noted between CD and AD subjects at enrollment. 
However, as the CD subjects were 5 years younger, this might signify an earlier diagnosis and treatment of hyper-
tension in the CD group. No information on potential counseling that AD subjects had received, such as the 
avoidance of kidney injury or increased water-drinking behavior, was recorded in the study.
In the untreated (placebo) arm, CD subjects experienced somewhat lower rates of change in TKV and eGFR than 
AD subjects, although the differences were not significant. Additional analyses using age at diagnosis as a continuous 
variable did not show significant effects on outcomes. Despite the aforementioned risk factors for rapid progression, 
placebo treated CD subjects had a significantly better eGFR (mean difference 2.18 mL/min/1.73 m2 [p = 0.0475]) at 
the end of follow-up than predicted. By contrast, the prediction model was accurate in AD subjects (mean differ-
ence 0.07 mL/min/1.73 m2 [p = 0.8995]). The significant difference between observed and predicted eGFR in the 
CD group must be interpreted within the context of multiple comparisons and the possibility of a chance finding. 
Although the Mayo prediction equation is validated and commonly used as a clinical tool, a sensitivity analysis 
based on the mixed polynomial prediction model recently developed by Yu et al.17 found no significant differences 
in observed versus predicted eGFR in either tolvaptan- or placebo-treated subjects defined by age at diagnosis.
Several comments need to be made on the Mayo prediction model. First, the validity of the prediction equa-
tion is not documented for young patients, as it based on a vast majority of adult patients. With a mean age at 
inclusion of CD patients of 32.2 years this should not be an issue. More important, the trajectory of eGFR loss is 
often nonlinear and initially relatively stable when kidney function is still preserved. This renders the estimate 
less accurate in patients with CKD stage 116. As the CD group contains more CKD stage 1 patients, this could 
have played a role in the difference between the observed and predicted GFR. Indeed, when subjects with CKD 
stage I were excluded, the difference between the observed and predicted GFR disappeared. Moreover, while the 
tolvaptan-treated CD group expectedly performed better than predicted, the difference (6.86 mL/min/1.73 m2 in 
3 years) was quite large. While in placebo-treated subjects in the AD group the rate of eGFR loss was on average 
what was predicted (0.07 mL/min/1.73 m2), this is surprising because the difference between placebo and tol-
vaptan treatment was actually 0.98 mL/min/1.73 m2 per year in the TEMPO 3:4 trial. These findings suggest that 
application of the Mayo prediction model has limitations that should be taken into account in the interpretation 
of the present study.
Although a lack of power should be acknowledged, additional reason for caution is provided by subgroup 
analyses that accounted for differences between CD and AD subjects in age at study inclusion, Mayo risk class, and 
CKD stage, and which found no significant differences between predicted and observed eGFR in placebo-treated 
CD subjects. Similarly, in subgroups of placebo-treated CD subjects defined by reason for ADPKD diagnosis, 
there were no significant differences between predicted and observed eGFR.
Despite a more severe risk profile of the CD subjects, some analysis of the current post hoc study suggested a 
less rapid disease course of this group than predicted. However, other analyses could not confirm this finding and 
more studies are therefore needed before conclusions can be drawn. Although the current data do not contradict 
the attractive hypothesis that early targeting of risk factors for disease progression, such as hypertension, protein-
uria and urological complications could improve the natural history of the disease, this needs to be validated in 
studies with a more adjusted design.
Since CD patients were diagnosed earlier, they could theoretically be targeted early with disease-modifying 
treatments. However, several limitations for such strategies are to be taken into consideration. Although different 
prognostic indicators have been identified in adults16,23, no stratification risk factors for progression are validated 
for children10. Nevertheless, because parenchymal destruction already occurs under the cover of compensated 
GFR values27, such indicators are required in order to accurately identify patients at risk for rapid progression. 
Earlier treatment restricted to those at risk for rapid disease progression might improve both cost-effectiveness 
and the benefit-to-risk ratios of therapies. It is noteworthy that tolvaptan therapy was associated with similarly 
decreased rates of TKV growth and eGFR decline in both the CD and AD groups. Both the TEMPO 3:4 and the 
REPRISE studies demonstrated a greater efficacy of tolvaptan in rapidly progressing subjects. Ongoing studies, 
such as a phase IIIb trial of tolvaptan in ADPKD-affected children aged 4 to 18 years (NCT02442674), might 
make the need for prognostic assessment even more relevant.
While tolvaptan is the only disease modifying treatment currently available, it’s considerable side effect pro-
file should be taken into account in young patients. Specifically, the increased aquaresis that can be associated 
with hydroureteronephrosis and bladder enlargement as demonstrated in children with nephrogenic diabetes 
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insipidus warrants caution28. Future studies are needed to evaluate disease-modifying therapies in young ADPKD 
populations and to delineate balanced safety profiles compatible with a long-term treatment.
This study is limited by its post hoc nature. Such analyses are nonetheless useful for generating hypotheses for 
future study. The data reported explore the possibility that earlier diagnosis and initiation of ADPKD manage-
ment might improve renal function over the long-term. More prospective studies from a young age could refine 
prognostic tools, including genetic diagnosis, and determine treatment strategies with optimal risk-benefit pro-
files for the individual patient.
Received: 23 July 2019; Accepted: 21 February 2020;
Published: xx xx xxxx
References
 1. Chebib, F. T. & Torres, V. E. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am. J. Kidney Dis. 67, 792–810 
(2016).
 2. Grantham, J. J. et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int. 73, 108–116 
(2008).
 3. De Rechter, S. et al. Clinicians’ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney 
disease. Plos One. 12, e0185779 (2017).
 4. Torres, V. E. Pro: tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 34, 
30–34 (2019).
 5. Schrier, R. W. et al. Blood pressure in early autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2255–2266 (2014).
 6. Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).
 7. Torres, V. E. et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed 
treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol. Dial. Transplant. 33, 
477–489 (2018).
 8. Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930–1942 (2017).
 9. Edwards, M. E. et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. 
Nephrol. 13, 1153–1161 (2018).
 10. De Rechter, S., Bammens, B., Schaefer, F., Liebau, M. C. & Mekahli, D. Unmet needs and challenges for follow-up and treatment of 
autosomal dominant polycystic kidney disease: the paediatric perspective. Clin. Kidney J. 11(Suppl 1), i14–i26 (2018).
 11. De Rechter, S. et al. ADPedKD: a global online platform on the management of children with ADPKD. Kidney Int. Rep. 4, 1271–1284 
(2019).
 12. Gimpel, C. et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney 
disease in children and young people. Nat. Rev. Nephrol. 15, 713–726 (2019).
 13. Torres, V. E. et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant 
Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am. J. Kidney Dis. 57, 692–699 (2011).
 14. Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009).
 15. Horio, M., Imai, E., Yasuda, Y., Watanabe, T. & Matsuo, S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation 
for Japanese: accuracy and use for population estimates. Am. J. Kidney Dis. 56, 32–38 (2010).
 16. Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients 
for clinical trials. J. Am. Soc. Nephrol. 26, 160–172 (2015).
 17. Yu, A. S. L. et al. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 95, 
1253–1261 (2019).
 18. Helal, I. et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin. 
J. Am. Soc. Nephrol. 6, 2439–2443 (2011).
 19. Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B. & Schrier, R. W. Glomerular hyperfiltration: definitions, mechanisms and clinical 
implications. Nat. Rev. Nephrol. 8, 293–300 (2012).
 20. Messchendorp, A. L. et al. Kidney function reserve capacity in early and later stage autosomal dominant polycystic kidney disease. 
Clin. J. Am. Soc. Nephrol. 13, 1680–1692 (2018).
 21. Grantham, J. J. & Torres, V. E. The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat. 
Rev. Nephrol. 12, 667–677 (2016).
 22. Chapman, A. B. et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. 
Nephrol. 7, 479–486 (2012).
 23. Cornec-Le Gall, E. et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney 
disease. J. Am. Soc. Nephrol. 27, 942–951 (2016).
 24. Cornec-Le Gall, E., Audrézet, M. P., Le Meur, Y., Chen, J. M. & Férec, C. Genetics and pathogenesis of autosomal dominant 
polycystic kidney disease: 20 years on. Hum. Mutat. 35, 1393–1406 (2014).
 25. Bergmann, C. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr. 
Nephrol. 30, 15–30 (2015).
 26. Groopman, E. E. et al. Diagnostic utility of exome sequencing for kidney disease. N. Engl. J. Med. 380, 142–151 (2019).
 27. Grantham, J. J. Rationale for early treatment of polycystic kidney disease. Pediatr. Nephrol. 30, 1053–1062 (2015).
 28. Shalev, H., Romanovsky, I., Knoers, N. V., Lupa, S. & Landau, D. Bladder function impairment in aquaporin-2 defective nephrogenic 
diabetes insipidus. Nephrol. Dial. Transplant. 19, 608–613 (2004).
Acknowledgements
The authors thank BioScience Communications, Inc (New York, NY, USA), for assistance in editing the manuscript, 
support that was funded by Otsuka Pharmaceutical Development & Commercialization, Inc. The authors also thank 
Jennifer Lee and Wen-chyi Wang for statistical support. This research and the development of the manuscript were 
supported by Otsuka Pharmaceutical Development & Commercialization, Inc.
Author contributions
P.J., F.J., B.B., M.L., F.S., A.D., R.P., R.U., C.P. and D.M. contributed to the analysis and interpretation of the data, 
revising the manuscript, and providing substantial intellectual content and feedback at each stage of manuscript 
development. All authors gave final approval to the submitted manuscript. D.M. and C.P. are responsible for the 
study concept, and P.J., D.M., and C.P. drafted the manuscript.
8Scientific RepoRtS |         (2020) 10:4294  | https://doi.org/10.1038/s41598-020-61303-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
competing interests
P.J. has nothing to disclose. F.J. has received financial support from Otsuka to attend scientific meetings and 
advisory boards. B.B. has received research support from Amgen, Astellas, Novartis, Otsuka, and Roche, 
speaker fees from Baxter, and support to attend advisory boards from Novartis and Otsuka. M.C.L. has received 
honoraria for scientific lectures from Pfizer and is an advisory board member for Otsuka as a representative of 
the University Hospital of Cologne. F.S., represented by Heidelberg University Hospital, received an educational 
grant from Otsuka and participated in advisory boards. A.D. and C.S.P. are employees of Otsuka. R.D.P. 
(represented by Tufts Medical Center) was a member of the advisory committee that advised Otsuka for both 
the TEMPO and REPRISE studies; he has received research support for clinical trials from Otsuka, Kadmon, 
the US Dept. of Defense, and Sanofi; and presently serves as an advisor to Sanofi for the STAGED-PKD trial. 
Additionally, he serves as an advisor to Palladio Biosciences and Vertex, has received travel expenses and 
honoraria from Otsuka, Spain for scientific lecture; and is section editor for UpToDate Wolters Kluwer. R.-U.M. 
received honoraria for scientific lectures and counseling from Otsuka and Thermo Fisher Scientific. The Dept. 2 
of Internal Medicine Cologne was supported by research funding from Otsuka. D.M., represented by University 
Hospitals Leuven and KU Leuven University, received an educational grant from Otsuka and participated in an 
advisory board.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-61303-9.
Correspondence and requests for materials should be addressed to D.M.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
